Form 4: Acrivon Therapeutics Director Acquires RSUs

Acrivon Therapeutics Director Palani Santhosh acquired 9,366 restricted stock units (RSUs) on May 18, 2026, which are set to vest on May 18, 2027.

Summary

• Palani Santhosh, a Director at Acrivon Therapeutics, Inc., acquired 9,366 restricted stock units (RSUs) on May 18, 2026.
• These RSUs represent a contingent right to receive one share of the Issuer's Common Stock per unit.
• The RSUs are scheduled to vest in full on May 18, 2027, contingent upon Mr. Santhosh's continued service with the company through that date.
• The acquisition was made under a Rule 10b5-1(c) plan, indicating it was pre-arranged to satisfy affirmative defense conditions.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard equity grant to a director, signaling commitment but not immediate financial performance changes.

Positives

• Director acquisition of equity signals confidence in the company's future prospects.
• The acquisition was made under a Rule 10b5-1(c) plan, suggesting a structured and compliant approach to equity transactions.
• The vesting schedule aligns the director's incentives with long-term company performance.

Risks

• The RSUs are subject to forfeiture if the reporting person's continuous service through the vesting date is not met.
• The value of the RSUs is tied to the future performance and stock price of Acrivon Therapeutics, which carries inherent market risk.

Future Outlook

The RSUs are set to vest on May 18, 2027, subject to the reporting person's continued service, indicating a forward-looking incentive tied to long-term commitment.

Industry Context

StockSavvy.ai notes that director acquisitions of equity, particularly through pre-arranged plans like Rule 10b5-1(c), are common in the biotechnology sector as a means to align executive incentives with shareholder value and manage personal trading windows.

Stakeholder Impact

• Shareholders: The acquisition by a director may be viewed positively as a sign of commitment, potentially influencing investor confidence.
• Employees: The vesting schedule aligns director incentives with long-term company success, which can indirectly benefit employees through company growth.

Next Steps

• Continuous service by Palani Santhosh through May 18, 2027, for the RSUs to vest.

Key Dates

Keywords

Acrivon Therapeutics, ACRV, Form 4, SEC Filing, Restricted Stock Units, RSUs, Director, Equity Award, Beneficial Ownership, Vesting Schedule, Rule 10b5-1(c)